Incannex Development Update for IHL-42X for Obstructive Sleep Apnoea (‘OSA’)

November 17, 2022

https://www.globenewswire.com/news-release/2022/11/17/2558126/0/en/Incannex-Development-Update-for-IHL-42X-for-Obstructive-Sleep-Apnoea-OSA.html

Highlights:

MELBOURNE, Australia, Nov. 17, 2022 (GLOBE NEWSWIRE) — Incannex Healthcare Limited (Nasdaq:IXHL) (ASX:IHL), (‘Incannex’ or the ‘Company’) a clinical-stage pharmaceutical company developing unique medicinal cannabinoid pharmaceutical products and psychedelic medicine therapies for unmet medical needs, is pleased to announce that Incannex has initiated a BA/BE study and is targeting submission of an IND application with the FDA in Q1 2023.

Read more at globenewswire.com

Related news for (IXHL)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.